Cabozantinib seems to be a very good second-line therapy for patients with mRCC, having very good results of PSF or OS in comparison with other therapeutics used in the treatment of RCC due to wide spectrum of targeted kinases, especially c-Met and AXL. This evidence concerns the gene MET and renal cell carcinoma.